title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Group VS | The video stylet (TRS K2, UE Medical Equipment Co., Ltd., Zhejiang, China, Fig. | PMC10512610 | ||
Group FV | The flexible videoscope (TIC, UE Medical Equipment Co., Ltd., Zhejiang, China, Fig. After successful tracheal intubation, the patient was connected to the anesthesia machine for mechanical ventilation, the tidal volume was adjusted to 10 ml/kg, and the respiratory rate 12 breaths/min to maintain PETCO | PMC10512610 | ||
Patient evaluation | The success rate of the first intubation was recorded as the primary observation. The level of glottic exposure (Wilson-Cormack-Lehane grading, W–C-L) [ | PMC10512610 | ||
Statistical analyses | To calculate the sample size, we performed a preliminary experiment with 20 patients in each group (60 patients in total), and the first-pass intubation success rate in each group was 75% in Group VL, 95% in Group VS, and 90% in Group FV. With The data were analyzed using SPSS 26.0 statistical software. Continuous vari... | PMC10512610 | ||
Discussion | ’s mouth, glottis, epiglottis | In this randomized parallel-group study, we showed that all three devices were ultimately effective for intubation, higher first-pass intubation success rates were obtained with the video stylet and the flexible videoscope. Endotracheal intubation with the video stylet resulted in shorter intubation time when compared ... | PMC10512610 | |
Conclusion | hypoxia | HYPOXIA | When managing the airway of patients with difficult airways, all three devices can be used to achieve high intubation success rates, but the video stylet and flexible videoscope provide a better view of the vocal cords and are superior to the video laryngoscope in terms of the first-pass intubation success rate. The us... | PMC10512610 |
Acknowledgements | We acknowledge the assistance of American Journal Experts (AJE) for English language editing. | PMC10512610 | ||
Authors’ contributions | TZ and RHL designed the study and drafted the manuscript. PZ completed the anesthesia management. KYZ enrolled patients. All authors read and approved the final manuscript. | PMC10512610 | ||
Funding | This research was funded by the Research Fund Project at the Hospital Level of Luan Hospital, Anhui Medical University (2021kykt05). | PMC10512610 | ||
Availability of data and materials | The datasets used and/or analyzed during the current study were available from the corresponding author on reasonable request. | PMC10512610 | ||
Declarations | PMC10512610 | |||
Ethics approval and consent to participate | The present study was approved by the Ethics Committee of the Affiliated Luan Hospital, Anhui Medical University (NO. 2021LL005), and written informed consent forms were signed by all the participants or their relatives before enrollment. As part of our study, we adhere to established international standards, including... | PMC10512610 | ||
Competing interests | The authors declare that they have no competing interests. | PMC10512610 | ||
References | PMC10512610 | |||
Purpose | METASTATIC BREAST CANCER | PUFFIN (NCT02896855), a Chinese bridging study in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer, assessed consistency of efficacy and safety of pertuzumab plus trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel, with CLEOPATRA (NCT00567190). | PMC9883304 | |
Methods | Eligible patients, | PMC9883304 | ||
Results | Updated median PFS: 16.5 months (pertuzumab arm) and 12.5 months (placebo arm), with a hazard ratio (HR) of 0.60 [95% confidence interval (CI) 0.45, 0.81; | PMC9883304 | ||
Keywords | PMC9883304 | |||
Mathematics Subject Classification | PMC9883304 | |||
Introduction | diarrhea | ADVERSE EVENTS, METASTATIC BREAST CANCER, MUCOSAL INFLAMMATION, FEBRILE NEUTROPENIA | Pertuzumab and trastuzumab (PERJETAPertuzumab plus trastuzumab and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer was shown to improve progression-free and overall survival (PFS and OS) significantly compared with placebo plus trastuzumab and docetaxel in CLE... | PMC9883304 |
Methods | HER2-positive | ONCOLOGY, DISEASE, METASTATIC BREAST CANCER, METASTATIC DISEASE | PUFFIN was a phase III, randomized, double-blind, placebo-controlled study conducted across 15 centers in China. The protocol was approved by the institutional review board at each participating site. Informed consent was provided from all participants. The study design, eligibility criteria, procedures, assessments, a... | PMC9883304 |
Procedures | visceral disease | Randomization was 1:1, using visceral disease and hormone receptor status to stratify patients to pertuzumab (840 mg loading dose, followed by 420 mg every 3 weeks), trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks), and docetaxel (75 mg/mAfter the primary analysis, patients could cross over from the place... | PMC9883304 | |
Statistical methods | PFS and OS were estimated using the Kaplan–Meier approach. HR and 95% CIs were estimated by a Cox proportional hazard model using the stratification factors. To compare the two arms, a two-sided stratified log-rank test was used. Statistical testing was considered exploratory. Safety analyses were descriptive. | PMC9883304 | ||
Results | PMC9883304 | |||
Study population | From 13 September 2016 to 28 September 2017, 243 eligible patients were randomized: 122 and 121 to the pertuzumab and placebo arms, respectively [Disposition of patients | PMC9883304 | ||
Progression-free survival | Updated median investigator-assessed PFS was 16.5 months (95% CI 12.7, 20.2) in the pertuzumab arm and 12.5 months (95% CI 10.4, 14.6) in the placebo arm (Fig. Investigator-assessed PFS in | PMC9883304 | ||
Overall survival | Median OS was not reached in either arm. The stratified HR was 0.68 (95% CI 0.45, 1.03; OS in | PMC9883304 | ||
Treatment exposure | Prior to crossover, the median number of pertuzumab or placebo cycles administered to patients was 22.0 (range 1–4) and 17.0 (range 1–68), over the respective median duration of 66.1 weeks (range 3–225) and 52.3 weeks (range 3–207). The median number of trastuzumab cycles in the pertuzumab and placebo arms was 22.0 (ra... | PMC9883304 | ||
Discussion | Leukopenia, pneumonia, neutropenia, diarrhea, leukopenia, febrile neutropenia, anemia, hypertension | LEUKOPENIA, PNEUMONIA, NEUTROPENIA, LEUKOPENIA, FEBRILE NEUTROPENIA, DISEASE, ANEMIA, HYPERTENSION | PUFFIN previously met its primary objectives, demonstrating consistency of efficacy with CLEOPATRA [Subgroup analyses showed consistency with the overall PFS and OS results. Compared with the primary PFS subgroup analysis, the final analysis showed an overall shift toward the pertuzumab group having improved PFS and OS... | PMC9883304 |
Conclusions | METASTATIC BREAST CANCER | This final analysis of PUFFIN showed, as with the primary analysis, that overall efficacy was consistent with that of the ITT population in CLEOPATRA. Safety of pertuzumab remained consistent with the known pertuzumab profile. Overall, PUFFIN contributes to the totality of data with pertuzumab in previously untreated H... | PMC9883304 | |
Author contributions | All authors contributed to drafting the work or revising it critically for important intellectual content and read and approved the final the version of the manuscript to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any ... | PMC9883304 | ||
Funding | This work was supported by F. Hoffmann-La Roche Ltd, Basel, Switzerland (no grant number applicable). F. Hoffmann-La Roche Ltd was involved in the study design, data interpretation, and the decision to submit for publication in conjunction with the authors. | PMC9883304 | ||
Data availability | For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli. | PMC9883304 | ||
Declarations | PMC9883304 | |||
Conflict of interest | WL, HL | BX reports institutional research funding (investigator fees for this study to his institution) from F. Hoffmann-La Roche Ltd; and consultant/advisory roles for Novartis, Roche, and AstraZeneca. WL, QZ, QL, XW, HL, TS, YY, HZhe, and JF all report institutional research funding (investigator fees for this study) from F.... | PMC9883304 | |
Ethics approval | ICH | This study was conducted in full conformance with the International Council for Harmonisation (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or with the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to... | PMC9883304 | |
Consent to participate | Written informed consent for participation in the study had to be obtained before performing any study-specific screening tests or evaluations. Informed consent forms for enrolled patients and for patients who were not subsequently enrolled were maintained at the study site. | PMC9883304 | ||
Consent for publication | Not applicable. | PMC9883304 | ||
References | PMC9883304 | |||
Purpose | rUTI | RECURRENT URINARY TRACT INFECTION | To evaluate efficacy and safety of vaccination with StroVac compared to placebo in patients with recurrent urinary tract infections (rUTI). | PMC9870822 |
Material and methods | UTI, rUTI | BACTERIAL URINARY TRACT INFECTION, RECURRENCES, RECURRENCE, UTI | We performed a prospective, double-blinded, placebo-controlled study in patients with uncomplicated rUTI. Patients received three single intramuscular injections with StroVac every two weeks. Primary endpoint was the number of bacterial urinary tract infections (UTI) over 13.5 months after randomization and adjusted by... | PMC9870822 |
Results | 376 patients were randomized to both groups between January 2012 and March 2015. Mean age was 44.4 years. Patients were mainly female (98.4%). In the StroVac group ( | PMC9870822 | ||
Conclusion | UTIs, rUTI | StroVac reduced the number of clinically relevant UTIs like in former studies but did not show statistically significant better results than the chosen placebo. Most likely, that was due to a, since confirmed, prophylactic effect of the chosen placebo itself. Therefore, placebo-controlled and double-blinded studies usi... | PMC9870822 | |
Keywords | PMC9870822 | |||
Introduction | UTI, rUTI | DISEASE, URINARY TRACT INFECTIONS, UTI | Urinary tract infections (UTI) are a common disease affecting 11% of women worldwide at least once per year [StroVac offers a different approach consisting of 10 strains of inactivated uropathogens: six of Therefore, we conducted a prospective, multicentre, randomized, double-blinded and placebo-controlled study on eff... | PMC9870822 |
Patients and methods | ICH | This double-blinded, randomized and placebo-controlled phase IV study was conducted from January 2012 to March 2015 in 40 sites in Germany. This study was conducted in compliance with the ICH Guideline E6 (R1) on Good Clinical Practice and registered under EudraCT no. 2010-020882-25. Several ethic committees were invol... | PMC9870822 | |
Study participants | lower urinary tract symptoms, malignancy, diabetes mellitus, rUTI, liver or renal insufficiency, systemic infectious disease, neurogenic bladder dysfunction, bladder or kidney stones, UTIs | DIABETES MELLITUS, CONCOMITANT DISEASE, NEUROGENIC BLADDER DYSFUNCTION, UTI, SYSTEMIC INFECTIOUS DISEASE, COMPLICATIONS | Patients of both sexes aged 18–80 years were included if they had at least five symptomatic uncomplicated bacterial UTIs within 12 months prior to study inclusion. In accordance with current literature, UTI diagnosis required a positive urine culture with ≥ 10Exclusion criteria comprised complicated UTI, lower urinary ... | PMC9870822 |
Endpoints | bacterial UTIs, UTIs | RECURRENCES, RECURRENCE | The primary endpoint was the number of bacterial UTIs over 13.5 months after randomization adjusted by the respective “baseline” value (ITT-population) when comparing verum and placebo group. Baseline adjustment was done by including the respective baseline value as covariate into the statistical model. Secondary endpo... | PMC9870822 |
Study medication | The investigational medicinal products consisted of a basic suspension and a dry substance for preparing the suspension for injection. Finished verum suspension for one injection contained at least 10 | PMC9870822 | ||
Statistical analysis | UTIs | RECURRENCES, RECURRENCE | The sample size calculation was based upon an average of 6.2 UTIs in the year pre-study, a 50% placebo response and an additional 15% StroVac effect in reducing UTIs during the study period. The number of 6.2 UTIs was calculated from data of an earlier study [The efficacy analyses were performed using the intention to ... | PMC9870822 |
Results | UTIs, rUTI | RECURRENCES, RECURRENCE, UTI | Of the 412 patients screened for eligibility, 376 patients were randomized equally to both groups between January 2012 and March 2015 (i.e. 188 patients per group, see Table Characteristics of patients with rUTI under prophylaxis with StroVac or placeboThe Results are presented as: mean and standard deviation (SD) and ... | PMC9870822 |
Subgroup analysis | cystitis, UTIs | RECURRENCES, CYSTITIS, UTI | In premenopausal women, no statistically significant difference was seen between the two treatment groups in the frequency of recurrences (In patients older than 70 years, the reduction of frequency of UTI (by 4.4–4.5 UTIs, Using a broader UTI definition (patients with self-documented UTIs without visiting a doctor, wi... | PMC9870822 |
Patient-reported outcomes/quality of life questionnaires (QoL) | UTI | In the StroVac group, complaints recorded in most QoL questionnaires were reduced by approximately 50% from V1 (baseline) to V9, in parallel to the reduction of UTI frequency. The mean scores of “symptom burden”, "mental consequences", and "effect on daily life" declined from 21.2 to 10.2, from 11.8 to 5.9, and from 9.... | PMC9870822 | |
Safety results | pyrexia, influenza-like illness, nasopharyngitis, pain | ADVERSE EVENTS, EVENT, INFLUENZA-LIKE ILLNESS, NASOPHARYNGITIS | Overall, 619 adverse events (AE) occurred within the treatment period, 426 AEs in the StroVac group in 115 patients (62.2%), and 193 AEs in 83 patients in the placebo group (44.1%). By the end of the study, most AEs had resolved (98.7%). Most AEs were mild (54.9%) and moderate (33.4%) in intensity, and 11.6% were class... | PMC9870822 |
Discussion | StroVac reduced rUTI, urinary tract infections, fever, rUTI, UTIs | RECURRENCE, URINARY TRACT INFECTIONS, PERTUSSIS, FLU-LIKE ILLNESS, UTI, HEAT | Due to the emerging possibilities in non-antibiotic prophylaxis and a growing body of evidence proving their efficacy [Since the aim of the study was to prove the efficacy of StroVac in prophylaxis of rUTI, one has to state, that our study showed no significant advantage of StroVac over the placebo we used. We even saw... | PMC9870822 |
Author contributions | SP and AHH designed the study, SN wrote the manuscript with input from CP, AHH, WV, WF and AN, AN and SN edited the manuscript. | PMC9870822 | ||
Funding | This research was performed under funding of Strathmann GmbH & Co. KG. | PMC9870822 | ||
Declarations | PMC9870822 | |||
Conflict of interest | FABRY | S Nestler works as an advisor/author for Dermapharm, Strathmann, Abbvie, GlaxoSmithKline. S Peschel and AH Horstmann are employees of Strathmann GmbH & Co. KG. W Vahlensieck works as advisor/author for Apogepha, Bene, Bionorica, Strathmann, Fresenius, Infectopharm, Medice, Perrigo, Repha. W Fabry have no conflicts of i... | PMC9870822 | |
Ethical approval | ICH | This study was conducted in compliance with the ICH Guideline E6 (R1) on Good Clinical Practice and registered under EudraCT no. 2010-020882-25. Several ethic committees were involved, including a leading committee in Berlin and local ethic committees in regions with participating centres. Informed consent was obtained... | PMC9870822 | |
References | PMC9870822 | |||
Subject terms | CKD | SECONDARY | We investigated the effect of two dosing regimens of oral iron on iron status and hematological parameters in patients with CKD. In this single center, open label, randomized, active controlled clinical trial, stable adult patients with CKD stage G3–4 with percentage transferrin saturation (%TSAT) ≤ 30% and serum ferri... | PMC9813132 |
Introduction | Anemia, CKD, chronic kidney disease, CVD | CVD, ANEMIA, CARDIOVASCULAR DISEASE | Anemia is common in chronic kidney disease (CKD) and has been associated with impaired quality of life, cardiovascular disease (CVD) and mortalityIn patients with CKD who are not on dialysis, oral route may be preferred as initial mode of iron supplementation. Oral iron is inexpensive, self-administered, convenient and... | PMC9813132 |
Methods | PMC9813132 | |||
Study design | The study was a single centre, pilot study. It was parallel arm, randomized, open label, active controlled, interventional trial conducted at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. The trial was approved by the Institute Ethics Committee of PGIMER, Chandigarh and prosp... | PMC9813132 | ||
Study population | TSAT ≤, CKD | All adults with a diagnosis of CKD stage G3–4 attending the outpatient clinic at PGIMER were eligible for screening. Subjects between the ages of 18 and 70 years, TSAT ≤ 30%, serum ferritin ≤ 500 mg/L | PMC9813132 | |
Enrolment and randomization | At enrolment, all participants entered 2-week run-in period. This was done to ensure clinically stable status of participants. The visit scheduled after completion of run-in period was referred to as baseline visit. Participants were randomized in 1:1 allocation ratio to either of the two study groups at baseline visit... | PMC9813132 | ||
Intervention and follow up | ADVERSE EVENTS | Participants were randomized to oral iron supplementation with ferrous ascorbate in either once daily (100 mg of elemental iron once daily i.e., 100 mg total daily dose, referred to as OD group) or twice daily (100 mg elemental iron twice daily i.e., 200 mg total daily dose, referred to as BD group) dosing for 12 weeks... | PMC9813132 | |
Outcomes | hypochromic red blood cells | SECONDARY | The primary outcome was difference in change in % TSAT over 12 weeks between the two groups. The secondary outcomes were differences in changes in serum ferritin, blood hemoglobin concentrations, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), percenta... | PMC9813132 |
Measurements | BLOOD | All measurements were done in fasting blood samples. Blood hemoglobin concentrations, MCH, MCV, MCHC, % HYPO-He and RET-He were measured at every visit on Sysmex XN-1000™ Hematology Analyzer (Sysmex Corporation, Kobe, Japan). These measurements were done within 4 h of sample collection. % TSAT concentrations were calcu... | PMC9813132 | |
Statistical considerations | SD | REGRESSION, SECONDARY | Assuming dropout rate of 10%, a sample size of 80 participants (40 in either group) was required to detect absolute difference of 3% in % TSAT [standard deviation (SD) ± 4.5%] between the two groups with 80% power and two sided α of 0.05. All participants with non-missing outcome data were included in the analysis. Des... | PMC9813132 |
Ethics approval and consent to participate | Study was approved from the Institute Ethics Committee and patients were enrolled in this study after getting the written consent prior to study procedures. | PMC9813132 | ||
Change in iron status and hematological parameters in the study population | Serial measurements done at 2, 5 and 12 weeks in both the groups are shown in Supplementary Tables | PMC9813132 | ||
Adverse events and others | ADVERSE EVENTS | All participants who completed study were compliant with study medication. Minor adverse events were recorded during the study (Supplementary Table | PMC9813132 | |
Discussion | iron deficiency anemia, CKD, TIBC | IRON DEFICIENCY ANEMIA, IRON DEFICIENCY, SECONDARY | In our study, the changes in %TSAT, serum iron and TIBC did not differ significantly between OD and BD dosing groups over 12 weeks. However, serum ferritin increased significantly in the BD group as compared to the OD group. Either repletion of intracellular stores or sequestration of iron within the cellular stores wi... | PMC9813132 |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-022-26589-x. | PMC9813132 | ||
Acknowledgements | We are thankful to Junior Laboratory Technicians: Ms Kiran Khere and Mr Nand Lal in the Department of Paediatrics at PGIMER, Chandigarh for their help in carrying out the study. | PMC9813132 | ||
Author contributions | P.K. | Conceived and designed the work: S.V., K.V., P.B., S.M.; data acquisition (screening, enrolment, and follow-up of patients): V.S., K.V., R.R., M.R., H.S.K., K.L.G., T.S. and S.K.S.; laboratory measurements: P.B., P.K., K.K. and A.K.Y.; data analysis: K.K., M.K., A.G., K.V., A.K.Y.; manuscript: K.V., V.S., A.K.Y., P.B.,... | PMC9813132 | |
Funding | This study was funded in-part through grant received by VJ from Department of Biotechnology, Ministry of Science and Technology, India (Grant No. BT/PR11105/MED/30/1345/2014). The funding agency had no role in design and conduct of this study. | PMC9813132 | ||
Data availability | The datasets analysed during this study are available from the corresponding author on reasonable request. | PMC9813132 | ||
Competing interests | VJ has research grants from Baxter, GSK and reports Consultancy and Advisory Board honoraria from Baxter Healthcare, and AstraZeneca, outside the published work. All other authors reported no conflict of interest. | PMC9813132 | ||
References | PMC9813132 | |||
Introduction | Eating disorders, Bulimia nervosa, psychosomatic disorders, Anorexia nervosa, AN | Eating disorders (EDs) including Anorexia nervosa (AN) and Bulimia nervosa (BN) are severe psychosomatic disorders with lifetime prevalence among females ranging from 2–4% [EDs can be treated in a variety of treatment settings. Different treatment settings offer varying degrees of treatment intensity and treatment stru... | PMC10313003 | |
Materials and methods | PMC10313003 | |||
Participants and procedure | Data were drawn from a large clinical trial [ | PMC10313003 | ||
Overview of study. | Sixty-four patients with AN and 66 patients with BN were enrolled in the study. Fifty-nine patients with AN and 57 patients with BN participated. Potentially eligible patients who were voluntarily admitted between July 2014 and April 2017 to cooperating treatment centers were approached by staff members and informed ab... | PMC10313003 | ||
Cooperating sites and treatment | psychiatric | The study sites included nine treatment sites in western Germany and northern Switzerland, which provided CBT-based interventions in accordance with the national clinical practice treatment guideline for the treatment of ED [Full-time treatment consisted of 24/7-care in a medical or psychiatric hospital or a privately ... | PMC10313003 | |
Measures | PMC10313003 | |||
Diagnostic interview | DISORDERS | A clinician-administered, semi-structured diagnostic interview (DIPS; Diagnostic Interview for Mental Disorders) [ | PMC10313003 | |
Self-report questionnaire | Eating Disorder | PATHOLOGY | At pre- and post-measurement, all patients completed an online questionnaire including questions regarding age, education, nationality, relationships status, use of psychopharmaceutics, and number of cigarettes smoked per day. Symptoms of ED pathology were assessed by the global score of the Eating Disorder Examination... | PMC10313003 |
Body-Mass-Index (BMI) | At pre- and post-measurement, weight and height of study participants were measured using a calibrated electronic scale (Seca 899, Basel, Switzerland) and a stadiometer (Seca 213, Basel, Switzerland). BMI was calculated as weight in kilograms divided by height in meters squared. | PMC10313003 | ||
Remission rates | weight gain | REMISSION | Patients were considered fully remitted if they met the following criteria: a) Full remission based on diagnostic interview (i.e., after full criteria for AN/BN were previously met, none of the criteria have been met for a sustained period of time), b) BMI ≥ 18.5 and c) EDE-Q global score ≤ 2.77. Patients were consider... | PMC10313003 |
Treatment intensity and treatment characteristics | To examine treatment intensity and treatment characteristics, brief online questionnaires were administered to therapists at post-measurement. Items assessed the number of individual and group sessions as well as treatment components and treatment goals discussed with patients (a list of response options was provided).... | PMC10313003 | ||
Statistical analyses | Statistical analyses were conducted using SPSS 27 (IBM). To describe the total sample as well as subsamples by diagnosis (AN vs. BN) and setting (full-time treatment vs. ambulatory treatment), means, standard deviations, frequencies, and percentages of measured variables were reported. Statistical comparisons between g... | PMC10313003 | ||
Results | PMC10313003 | |||
Descriptive characteristics of patients | On average, patients with EDs were 22.8 years (Descriptive characteristics of patients between treatment settings are also displayed in | PMC10313003 | ||
Treatment components and treatment goals reported by patients and therapists three months after treatment admission. | Anorexia Nervosa, Bulimia Nervosa | Note: Treatment may continue after the three-months post-measurement (particularly among ambulatory patients).* Only assessed among patients with AN. AN = Anorexia Nervosa. BN = Bulimia Nervosa. | PMC10313003 | |
Descriptive statistics of treatment received within three months after admission (therapist-report). | Anorexia Nervosa, Bulimia Nervosa | Note: Treatment may continue after the three-months (particularly among outpatients). AN = Anorexia Nervosa. BN = Bulimia Nervosa. | PMC10313003 | |
Symptomatic changes (means, standard deviations, Cohen’s | Anxiety, Bulimia Nervosa, Anorexia Nervosa, Depression, Eating Disorder | Note. Amb. = Ambulatory, AN = Anorexia Nervosa, BN = Bulimia Nervosa, BMI = Body-Mass-Index, EDE-Q = Eating Disorder Examination Questionnaire, BDI = Beck Depression Inventory, BAI = Beck Anxiety Inventory, SOMS = Somatic Symptoms Scale. M = mean, SD = standard deviation, n = sample size, d = Cohen’s d. Descriptive sta... | PMC10313003 | |
Correlates of symptomatic improvements | weight gain | Among women with AN, a significant correlation was found only between weight gain and ED severity ( | PMC10313003 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.